Maternal and neonatal outcome and children ’s development after medically assisted reproduction with in-vitro matured oocytes—a systematic review and meta-analysis

AbstractBACKGROUNDIVM was implemented in medically assisted reproduction 25  years ago. IVM does not involve controlled ovarian stimulation (COS) and is mainly indicated in patients with a high risk of ovarian hyperstimulation syndrome, in particular in patients with polycystic ovary syndrome (PCOS); it is also an acknowledged option in fertility protection. However, thein-vitro culture of immature oocytes raises concerns over their developmental potential and the putative impact on children ’s health. Although an increasing number of studies on obstetric and neonatal outcomes of IVM children and their development have been published in recent years, study designs are difficult to compare, since IVM is used in women with various indications and IVM protocols do not follow the same sta ndards.OBJECTIVE AND RATIONALEThe aim of this systematic review was to evaluate the current evidence from IVM children of an impact ofin-vitro culture of immature oocytes. Primary outcome parameters were birthweight and children ’s development up to the age of 2 years. We also compared pregnancy pathologies and the outcome of IVM children and COS children in relation to maternal indications, in particular PCOS, and to the type of IVM protocols with or without ovulation trigger as the secondary outcome parameters. IVM is an accepted clinical option for many centres; however, a comprehensive analysis of the available data is needed to establish whether the use of human oocytes that are ful...
Source: Human Reproduction Update - Category: OBGYN Source Type: research